The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.

Expert Opin Drug Discov · 2016 · PMC4841022 · PMID 26971593

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the fixed-dose study, vilazodone 40 mg/day was significantly superior to placebo on the primary efficacy measure; the difference in mean reduction in HAMA score between vilazodone 20 mg/day and placebo did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.